Global Leukemia Academy

Webinar on Recent Updates in Pediatric and AYA ALL: Focus on Middle East Region


Aptitude Health organized this webinar, targeting the Middle East Region, focused on recent updates in pediatric and AYA ALL, including information from ASH 2019, ASCO 2020, EHA 2020, and EBMT 2020, as well as recent publications.

Experts shared their insights on enactment of new paradigms, including administration of new treatments such as bispecifics, and patient monitoring and management. They also discussed strategic implementation of minimal residual disease (MRD) monitoring.

Date and Location

Saturday, 14 November 2020
5.00 PM – 6.20 PM Arabia Standard Time/Turkey Standard Time (AST/TST)
4.00 PM – 5.20 PM Eastern European Time (EET)

Virtual Meeting

Meeting Content

View the slides and watch the video of the webinar on Recent Updates in Pediatric and AYA ALL: Focus on Middle East Region

Ask your questions directly to the experts and receive their personal insights on current and novel treatment approaches for pediatric and adult patients with acute leukemias.


Patrick Brown

Patrick A. Brown, MD

Johns Hopkins University
School of Medicine, USA

Franco Locatelli

Franco Locatelli, MD, PhD

University of Rome
IRCCS Ospedale Pediatrico
Bambino Gesù, Italy

Rupert Handgretinger

Rupert Handgretinger, MD, PhD

Children’s University Hospital and
Department of Hematology/Oncology,


This meeting was a 1 hour and 20-minute virtual event.
  Time Topic Presenter
  4.00 PM – 4.05 PM EET
5.00 PM – 5.05 PM AST/TST
(5 minutes)
Welcome and Introductions Rupert Handgretinger, MD
  4.05 PM – 4.20 PM EET
5.05 PM – 5.20 PM AST/TST
(15 minutes)
Current Paradigm and Long-Term Toxicities for Pediatric/AYA ALL
• Integration of innovative immunotherapies
• Role of MRD in treatment
• Long-term toxicities
Franco Locatelli, MD, PhD
  4.20 PM – 4.40 PM EET
5.20 PM – 5.40 PM AST/TST
(20 minutes)
Bispecifics for Pediatric/AYA ALL
• Review of trial results in pediatric/AYA ALL
• Role of MRD in research and treatment
• AYA considerations
Patrick Brown, MD
  4.40 PM – 4.55 PM EET
5.40 PM – 5.55 PM AST/TST
(15 minutes)
CAR T Cells for Pediatric/AYA ALL
• Benefits and risks of CAR Ts and bispecifics
• Role of MRD in research and treatment
• AYA considerations
Franco Locatelli, MD, PhD
  4.55 PM – 5.20 PM EET
5.55 PM – 6.20 PM AST/TST
(25 minutes)
Questions to Experts Rupert Handgretinger, MD